17
Feb

Novartis is gobbling up a startup biotech in the U.S. that could help provide an entry into the frenzied race for PD-1 targeting therapies, announcing this morning that it had struck a deal to buy CoStim Pharmaceuticals, a low-profile biotech based in Cambridge, MA, and listed as part of Atlas Venture’s group of companies.

…read more

Source: Novartis beefs up its cancer immunotherapy pipeline with a biotech buyout

    

0 No comments